Access DB# 4567

## SEARCH REQUEST FORM

# Scientific and Technical Information Center

Requester's Full Name: 3	cian Pelleggino	Examiner #: 77018 Date: 5/2//3
Art Unit: 3738 Phon	ne Number 30 6 58	99 Serial Number: 09/733120
Mail Box and Bldg/Room Loca	ttion:	Results Format Preferred (circle): PAPER DISK E-MAIL
If mor than one search is su	hmitted, places mul-	
Please provide a detailed statement of	the search tonic and de-	*************
Include the elected species or structure	es, keywords, synonyms,	cribe as specifically as possible the subject matter to be searched acronyms, and registry numbers, and combine with the concept or
known Please attach a conv of the	rms that may have a speci	acronyms, and registry numbers, and combine with the concept or all meaning. Give examples or relevant citations, authors, etc. if
•.•	- '	, and adstract.
Title of Invention:	Balloon Ca	the ter
Inventors (please provide full names	): Florencia	Lin Nign Jiong Dei
Chi Lox		
Earliest Priority Filing Date:	4/21/99	
*For Sequence Searches Only* Please in appropriate serial number.	clude all pertinent informati	ion (parent, child, divisional, or issued patent numbers) along with the
claim	•	
- a radially	noncompliant	balloon having a folded nonin flated configuration
7 1 11 10 4 1 1 1001	CO VANCERNEA.	
least in pait	of a polycar	bonate based asomatic adjust 1/2/
havias a comelia.	on of less the	about 0.025 mm/atm in the working prass
. 64 ( 11	1 . 1 . 1	malatan in the working prasa
the product of the ru	eaction of poli	The best 12 41 1 11 11 11 11 11 11 11 11 11 11 11 1
bis phony/ dilsolyan.	rte (MDI) and	(1,6 hoxy) 1,2 ethylcorbonate) did and 4,4 methylane
also called RIDAL	ATE	rein extender.
9,000	1110	•
		,- · · · · · · · · · · · · · · · · · · ·
· •		
		÷
****		
TAFF USE ONLY	*******	**********
earcher: John Cimi	Type of Search	Vendors and cost where applicable
- 0 6:0-1	NA Sequence (#)	STN
earcher Phone #:	AA Sequence (#)	Dialog
earcher Location:	Structure (#)	Questel/Orbit
ate Searcher Picked Up:	Bibliographic	Dr.Link
te Completed: 3/22/03	Litigation	Lexis/Nexis
archer Prep & Review, Time:	Fulltext	Sequence Systems
crical Prep Time:		
	Patent Family	
line Time:	Patent Family Other	WWW/Internet Other (specify)



# STIC Search Report

# STIC Database Tracking Number: 94562

TO: Brian Pellegrino

Location:

Art Unit: 3738

Thursday, May 22, 2003

Case Serial Number: 09/733120

From: John Sims

Location: EIC 3700

CP2, 2C08

Phone: 308-4836

john.sims@uspto.gov

### Search Notes

Not much retrieved on this. Inventor Lim holds a number of pate
---

Some reference to use of Bionate in biocompatible medical devices.



3/7/4 (Item 1 from file: 34)
DIALOG(R) File 34: SciSearch(R) Cited Ref Sci
(c) 2003 Inst for Sci Info. All rts. reserv.

06995262 Genuine Article#: 112NC Number of References: 87

Title: Cyclic carbonates and spiro-orthocarbonates - Prospective monomers in the chemistry of polymers

Author(s): Rokicki G (REPRINT); Kowalczyk T

Corporate Source: WARSAW UNIV SCI & TECHNOL, WYDZIAL CHEM, UL NOAKOWSKIEGO 3/PL-00664 WARSAW//POLAND/ (REPRINT)

Journal: POLIMERY, 1998, V43, N7-8, P407-415

ISSN: 0032-2725 Publication date: 19980000

Publisher: INDUSTRIAL CHEMISTRY RESEARCH INST, 8 RYDYGIERA STR, 01-793 WARSAW, POLAND

Language: Polish Document Type: ARTICLE

Abstract: Syntheses and applications of cyclic carbonates and spiro-orthocarbonates are reviewed with particular reference to the ring-size effect exercised by either carbonate type on the mechanisms of polymerization and copolymerization carried out with various heterocyclic monomers. Prospective application areas of the polycarbonates and their copolymers thus obtained are discussed. Aliphatic polycarbonates are used as polyol ingredients for segmented polyurethanes to make hydrolysis-resistant urethane elastomers as well as oxidation-resistant and biocompatible medical utensils (e.g., **BIONATE** ). Some aliphatic copolycarbonates (e.g., with (R)-beta-butyrolactone) are biodegradable; polycarbonates and copolymers containing polycarbonate blocks are liable to ring-closing depolymerization,, which thus renders thermodynamic recycling feasible. Modification of epoxy resins with cyclic carbonate-terminated oligomers, involving polyamines and Lewis acids (especially BF3. OEt2) as curing agents, has led to compositions endowed with enhanced impact resistance.

ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2003 ACS L1

ACCESSION NUMBER:

1999:686786 HCAPLUS

TITLE:

Stent deploying catheter system and balloon catheter

INVENTOR(S):

Lee, Jeong S.; Lim, Forencia

PATENT ASSIGNEE(S):

Advanced Cardiovascular Systems, Inc., USA

SOURCE:

PCT Int. Appl.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

1

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT :	NO.		KI	ND	DATE			A	PPLI	CATI	ои ис	ο.	DATE				
WO	9953	986		A:	2	1999	1028		W	0 19:	99-U	S881	5	1999	0421			
WO	9953	986		A:	3	1999	1229											
	W:	ΑE,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ;	
		DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	ĤR,	HU,	ID,	IL,	IN,	IS,	
		JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	
		MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	
		TM,	TR,	TT,	UA,	UG,	UΖ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	
		RU,	ТJ,	TM														
	RW:	GH,	GM,	KΕ,	LS,	MW,	SD,	SL,	SZ,	ŪĠ,	ZW,	ΑT,	BE,	CH,	CY,	DE,	DK,	
		ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	
		CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG						
AU	9936	607		A:	1	1999	1108		Α	U 19	99-36	5607		19990	0421			
AU	7493	31 .		B:	2	2002	0627											
EP	9813	85		A:	2	2000	0301		E	P 19	99-93	18770	)	19990	0421			
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB.,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	FI															
PRIORIT	Y APP	LN.	INFO	. :				Ţ	JS 1	998-6	53969	Э	Α	19980	0421			
								1	WO 1	999-ī	JS88:	15	W	19990	0421			

ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:160876 HCAPLUS

Angioplasty catheter system with adjustable balloon TITLE:

length

Lee, Jeong S.; Lim, Florencia; Stiger, INVENTOR(S):

> Cheryl; Voyles, Carolyn; Bavaro, Vincent Advanced Cardiovascular Systems, Inc., USA

SOURCE:

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT ASSIGNEE(S):

PATENT NO. KIND DATE APPLICATION NO. DATE ----US 6527741 B1 20030304 US 1999-469966 19991221 PRIORITY APPLN. INFO.: US 1999-469966 19991221

A resizable inflatable balloon, primarily for use with balloon catheters. The resizable inflatable balloon comprises a first portion and an adjacent second portion. The first portion is inflatable to a working diameter at a first pressure while the second portion does not substantially expand at the first pressure. The second portion does expand to the working diameter at a second pressure greater than the first pressure, so that subsequent inflation at the first pressure inflates the first portion and the second portion to the working diameter. The methods of resizing the inflatable members include placing the inflatable balloon in a mold and supplying inflation fluid to expand the second member to the working diameter. In practice, a catheter having the resizable inflatable balloon is guided through a patient's vasculature until the inflatable balloon is positioned in a desired region. Inflation fluid is supplied at the first pressure to inflate the first portion to the working diameter. The catheter is withdraw and the inflatable balloon is resized as described above. The catheter is reintroduced to the patient's vasculature and inflation fluid is then supplied at the first pressure to inflate both the first and second portions.

REFERENCE COUNT:

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2003 ACS

20

ACCESSION NUMBER: 2000:82506 HCAPLUS

DOCUMENT NUMBER: 132:255926

High-molecular-weight kininogen preadsorbed to glass TITLE:

surface markedly reduces neutrophil adhesion

Yung, Lin-Yue L.; Lim, Florencia; Khan, AUTHOR (S):

Mohammad M. H.; Kunapuli, Satya P.; Rick, Leonard;

Colman, Robert W.; Cooper, Stuart L.

Department of Chemical Engineering, University of CORPORATE SOURCE: Delaware, Newark, DE, 19716, USA

Biomaterials (2000), 21(4), 405-414

CODEN: BIMADU; ISSN: 0142-9612

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal L'ANGUAGE: English

Adsorbed proteins on biomaterial surfaces det. whether cells adhere, but rheol. variables are also crit. Neutrophil adhesion under well-defined radial flow conditions was studied on glass preadsorbed with plasma proteins or plasma protein domain fragments. Fibrinogen, low-mol.-wt. kininogen (LK), high-mol.-wt. kininogen (HK), cleaved HK (HKa), and

SOURCE:

recombinant HK domains 3 and 5 (D3 and D5H) were used. The no. of adherent cells on the HK and HKa surfaces was less than 10% that found on the fibrinogen absorbed surface. The degree of spreading was minimal and detachment of adherent neutrophils was obsd. HK and HKa contain binding sites for both anionic surfaces and neutrophils in the same domain (D5H). When adsorbed to surfaces, HK and HKa did not have the neutrophil binding sites available and therefore exhibited an anti-adhesive effect. Although D5H contains anionic surface binding sites, its small mol. size required a higher no. of adsorbed mols. to cover the surface before a significant decrease in cell adhesion was obsd. Since LK and D3 do not possess specific anionic surface binding sites, the adsorption of these proteins on glass was very low compared to HK and HKa. Thus, extensive cell adhesion and spreading were obsd. on the surfaces partially covered with preadsorbed LK and D3.

REFERENCE COUNT:

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1999:686786 HCAPLUS

TITLE: Stent deploying catheter system and balloon catheter

INVENTOR(S): Lee, Jeong S.; Lim, Forencia

PATENT ASSIGNEE(S): Advanced Cardiovascular Systems, Inc., USA

SOURCE: PCT Int. Appl. CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO.
                                         APPLICATION NO. DATE
                    KIND DATE
                     ----
                                          WO 1999-US8815
    WO 9953986
                     A2 19991028
                                                           19990421
    WO 9953986
                     A3 19991229
        W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
            DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
            JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
            MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
            TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
            RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
            ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 9936607
                      A1
                           19991108
                                         AU 1999-36607
                                                           19990421
    AU 749331
                           20020627
                      B2
                                          EP 1999-918770
    EP 981385
                      A2
                           20000301
                                                           19990421
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE. FI
PRIORITY APPLN. INFO.:
                                       US 1998-63969
                                                        A 19980421
                                       WO 1999-US8815
                                                        W 19990421
```

An intravascular catheter system for properly implanting a stent in a body lumen generally comprising a catheter having an elongated shaft with an inflatable balloon formed of compliant material and a stent mounted on the working length of the balloon. The balloon material is compliant within the working range of the balloon to provide substantial radial expansion. The wingless radially expansive balloon expands in a uniform manner, thereby producing uniform expansion and implantation of the stent. Another embodiment is directed to a balloon catheter having a semi-compliant balloon formed at least in part of a block copolymer. Axial elongation during inflation may be prevented by axial stretching or

orientation during balloon production process or by mechanical device fitted on the catheter.

L1 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1999:569967 HCAPLUS

DOCUMENT NUMBER: 131:327450

TITLE: Surface properties and hemocompatibility of

alkyl-siloxane monolayers supported on silicone rubber: effect of alkyl chain length and ionic

functionality

AUTHOR(S): Silver, James H.; Lin, Jui-Che; Lim, Florencia

; Tegoulia, Vassiliki A.; Chaudhury, Manoj K.; Cooper,

Stuart L.

CORPORATE SOURCE: Department of Chemical Engineering, University of

Wisconsin, Madison, WI, 53706, USA

SOURCE: Biomaterials (1999), 20(17), 1533-1543

CODEN: BIMADU; ISSN: 0142-9612

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Self-assembled monolayers of alkylsiloxanes supported on

poly(dimethylsiloxane) (PDMS) rubber were used as model systems to study the relation between blood compatibility and surface compn. The inner lumen of PDMS tubes were first treated with an oxygen plasma. resultant oxidized surfaces were post-derivatized by reaction with alkyltrichlorosilanes to form the monolayer films. The alkyl chain lengths used were slightly longer than in a previous study, and this may alter the phase-state of the monolayer from liq.-like to cryst. The chem. properties of the monolayer were controlled by varying the chem. compn. of the alkyltrichlorosilanes used. Terminal functionalities included Me, CF3, COOH, SO3H and (CH2CH2O)4OH. Surface derivatization was verified with static contact angle measurements and XPS. Blood compatibility was evaluated using a canine ex vivo arterio-venous series shunt model. Surfaces grafted with hydrophobic head groups such as CH3 and CF3 were significantly less thrombogenic than the surfaces composed of ionic head groups such as COOH and SO3H. Surfaces enriched in (CH2CH2O)4OH had an intermediate thrombogenicity. Silastic pump grade tubing and polyethylene tubing, used as controls were found to be the least thrombogenic of all the surfaces tested.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

1997:727253 HCAPLUS

DOCUMENT NUMBER:

127:294458

TITLE:

SOURCE:

XPS Study of Surface Composition of a Segmented

Polyurethane Block Copolymer Modified by PDMS End

Groups and Its Blends with Phenoxy

AUTHOR(S):

Wen, Jianming; Somorjai, Gabor; Lim, Florencia

; Ward, Robert

CORPORATE SOURCE:

Department of Chemistry and Materials Science Division Lawrence Berkeley National Laboratory, University of

California, Berkeley, CA, 94720, USA

Macromolecules (1997), 30(23), 7206-7213

CODEN: MAMOBX; ISSN: 0024-9297

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: Journal English

AB Quant. angle-resolved XPS was used to investigate surface modification of

a newly developed biomaterial, segmented polyurethane capped with poly(dimethylsiloxane) (PDMS) end groups, and its blends with phenoxy. The compn. of the freshly prepd. films are not in equil. but they can be equilibrated both in air and in water. The surface segregation of PDMS is found both in nonequil. and in equil. states. XPS data also indicate that the PDMS is enriched in the film surfaces of both air/polymer and glass substrate/polymer interfaces for the pure segmented polyurethane and its blends. The surface compn. is affected by annealing temp. and water. Below the polymer glass transition temp., there is a small increase in PDMS surface concn. during annealing. Above Tg, PDMS surface concn. can increase by a factor of 2. The presence of water will decrease the PDMS surface segregation at temps. both below and above Tg.

ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1997:477070 HCAPLUS

DOCUMENT NUMBER: 127:140498

TITLE: Surface modification of segmented polyurethaneureas

via oligomeric end groups incorporated during

AUTHOR(S): White, Kathleen A.; Ward, Robert S.; Gill, Rusty S.;

Lim, Florencia; Coviello, Sallie K.

CORPORATE SOURCE: The Polymer Technology Group Incorporated, Emeryville,

CA, 94608, USA

SOURCE: Surface Modification of Polymeric Biomaterials,

[Proceedings of the American Chemical Society Division

of Polymer Chemistry International Symposium on Surface Modification of Polymeric Biomaterials], Anaheim, Calif., Apr. 2-6, 1995 (1997), Meeting Date 1995, 27-33. Editor(s): Ratner, Buddy D.; Castner,

David Gordon. Plenum: New York, N. Y.

CODEN: 64TFAA

DOCUMENT TYPE:

Conference

LANGUAGE:

English

Polyurethanes based on polyols or polycarbonates and MDI were prepd., chain-extended with diamines, and then end-capped with aliph. amines, dimethylsiloxanes, polyoxyethylenes, or fluoroaliph. alcs. The elastomeric products with tailor-made surface properties were suitable for use in medical products with improved thrombosis resistance.

ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:347930 HCAPLUS

DOCUMENT NUMBER: 125:56108

Neutrophil adhesion on surfaces preadsorbed with high TITLE:

molecular weight kininogen under well-defined flow

conditions

AUTHOR (S): Yung, Lin-Yue L.; Lim, Florencia; Khan,

Mohammad M. H.; Kunapuli, Satya P.; Rick, Leonard;

Colman, Robert W.; Cooper, Stuart L.

CORPORATE SOURCE: Department of Chemical Engineering, University of

Delaware, Newark, DE, 19716, USA

SOURCE: Immunopharmacology (1996), 32(1-3), 19-23

CODEN: IMMUDP; ISSN: 0162-3109

PUBLISHER: Elsevier DOCUMENT TYPE: Journal LANGUAGE: English

The adhesion of neutrophils and other leukocytes to biomaterial surfaces is an important phenomenon in the host response to biomaterials because the no. of adherent leukocytes is often related to the inflammatory response after implantation. After adhering to biomaterial surfaces,

other leukocyte reactions, such as phagocytosis, respiratory burst, and protease release, may occur and result in the deterioration of the implanted biomaterial and injury to peripheral tissue. This study of neutrophil adhesion quant. characterizes neutrophil adhesion under well-defined laminar flow conditions using a radial flow chamber. In this rheol. well-defined system, the fluid shear rate on the surface varies continuously with radial position. This allows the study of shear-dependent behavior of neutrophil adhesion. Exploiting the variable shear rate in the radial flow chamber, the kinetics of neutrophil adhesion was obtained using automated video microscopy and image anal. to recursively acquire cell counts from multiple fields in different radial positions, and to quantify the surface d. of neutrophil as a function of time. Neutrophil adhesion was studied on glass preadsorbed with fibrinogen and high-mol.-wt. kininogen (HK). At a shear rate of 20 s-1, the no. of adherent cells on the preadsorbed fibrinogen surface was similar to that on bare glass, and the no. of adherent cells on the HK surface was less than 10% of that on the bare glass. We conclude that surfaces preadsorbed with HK are anti-adhesive to neutrophils.

L1 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:298983 HCAPLUS

DOCUMENT NUMBER: 12

125:18921

TITLE:

Polyurethanes containing covalently grafted

RGD-peptides

AUTHOR(S):

Lin, Horng-Ban; Lim, Florencia; Cooper,

Stuart L.

CORPORATE SOURCE:

Department Chemical Engineering, University Delaware,

Newark, DE, 19716, USA

SOURCE:

Advances in Science and Technology (Faenza, Italy) (1995), 12 (Materials in Clinical Applications),

385-392

CODEN: ASETE5

PUBLISHER: DOCUMENT TYPE: Techna Journal English

LANGUAGE: Peptides based on cell-adhesive regions of fibronectin, Arg-Gly-Asp-Ser (RGDS), and vitronectin, Arg-Gly-Asp-Val (RGDV), were covalently bound to a polyurethane backbone via amide bonds. The polymers studied included a PTMO-polyurethane control, a carboxylated version of the control polyurethane, and three different peptide grafted (GRGESY, GRGDSY, and GRGDVY) polyurethanes. On hydrated samples, XPS or ESCA showed a greater increase of nitrogen concn. for the peptide grafted polymers which suggests that grafting of the hydrophilic peptides to the polyurethane augments the hard segment enrichment at the surface. Upon dehydration, the nitrogen concn. decreased for all five polymers suggesting migration of the more hydrophobic PTMO soft segment to the surface. In vitro endothelial cell adhesion showed an increase of cell attachment on prehydrated RGD-contg. peptide grafted polyurethanes, but not on the other polymers. This results suggest an enhancement of peptide d. at the aq. interface, in good agreement with the XPS studies.

L1 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

1995:493057 HCAPLUS

DOCUMENT NUMBER:

122:273993

TITLE:

Surface and blood-contacting properties of

alkylsiloxane monolayers supported on silicone rubber

AUTHOR (S):

Silver, James H.; Hergenrother, Robert W.; Lin,

Jui-Che; Lim, Florencia; Lin, Horng-Ban;

Okada, Toshiyuki; Chaudhury, Manoj K.; Cooper, Stuart

L.

CORPORATE SOURCE: Dep. of Chemical Engineering, Univ. of Wisconsin,

Madison, WI, 53706, USA

SOURCE: Journal of Biomedical Materials Research (1995),

29(4), 535-48

CODEN: JBMRBG; ISSN: 0021-9304

PUBLISHER: Wiley
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Self-assembled monolayers of alkylsiloxanes supported on polydimethyl siloxane (PDMS) rubber were used as model systems to study the relation between blood compatibility and surface chem. The inner lumen of PDMS tubes was first treated with an oxygen plasma. The resultant oxidized surfaces were postderivatized by reacting them with alkyltrichlorosilanes to form the monolayer films. The chem. properties of the monolayers were controlled by varying the head-group chem. compns. Surface derivatization was verified using variable-angle XPS (XPS or ESCA). Blood compatibility was evaluated using a canine ex vivo arteriovenous series shunt model. Surfaces grafted with hydrophobic head-groups as -CH3 and -CF3 had significantly lower platelet and fibrinogen deposition than the surfaces composed of hydrophilic groups such as -CO2Me, -(CH2CH2O)3COMe, and -(OCH2CH2)3OH.

L1 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:686513 HCAPLUS

DOCUMENT NUMBER:

121:286513

TITLE:

The role of complement activation and cellular

interactions on the biocompatibility of polyurethanes

AUTHOR (S):

Lim, Florencia

CORPORATE SOURCE:

Univ. Wisconsin, Madison, WI, USA

SOURCE:

(1994) 231 pp. Avail.: Univ. Microfilms Int., Order

No. DA9410613

From: Diss. Abstr. Int. B 1994, 55(3), 1042

DOCUMENT TYPE:

LANGUAGE:

Dissertation English

AB Unavailable

L1 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

1994:563977 HCAPLUS

DOCUMENT NUMBER:

121:163977

TITLE:

Effect of polyol molecular weight on the physical properties and hemocompatibility of polyurethanes

containing polyethylene oxide macro-glycols

AUTHOR(S):

Silver, James H.; Myers, Craig W.; Lim,

Florencia; Cooper, Stuart L.

CORPORATE SOURCE:

Department of Chemical Engineering, University of

Wisconsin, Madison, WI, 53706, USA Biomaterials (1994), 15(9), 695-704

CODEN: BIMADU; ISSN: 0142-9612

DOCUMENT TYPE:

Journal

LANGUAGE:

SOURCE:

English

AB The phys. properties and hemocompatibility of polyurethanes contg. polyethylene oxide (PEO) of varying mol. wts. but const. wt. fraction of hard segment are investigated. The PEO mol. wts. studied were 600, 1450 and 8000. Anal. of polyurethane phase sepn. and crystallinity using dynamic-mech. anal. and DSC show that the degree of phase sepn. and crystallinity increase with polyol mol. wt., but level off at the highest mol. wts. The degree of water absorption increases substantially with increasing PEO mol. wt., leveling off at the highest mol. wt. Tensile

data show a max. in extensibility at a PEO mol. wt. 1450, while ultimate strength increasing with increasing segment length. When the materials are hydrated, there is a significant drop in the modulus, ultimate stress and ultimate elongation. Dynamic contact angle measurements show that surface hydrophobicity decreases as the soft-segment mol. wt. increases. Using electron spectroscopy for chem. anal. (ESCA) to det. the surface compn. of these polyurethanes, it was found that the hard segment content at the surface increases as the polyol block length decreases. The hemocompatibility of these polyurethanes was investigated in an ex vivo canine blood-contacting model. Only for the shortest block length studied, PEO-600, are differences in blood compatibility obsd. This material was the most thrombogenic. The PEO-1450 sample shows comparable blood compatibility to PEO-8000.

L1 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:610650 HCAPLUS

DOCUMENT NUMBER: 119:210650

TITLE: Effects of oligoethylene oxide monoalkyl(aryl) alcohol

ether grafting on the surface properties and blood

compatibility of a polyurethane

AUTHOR(S): Lim, Florencia; Yu, Xuehai; Cooper, Stuart

L.

CORPORATE SOURCE: Dep. Chem. Eng., Univ. Wisconsin, Madison, WI, 53706,

USA

SOURCE: Biomaterials (1993), 14(7), 537-45

CODEN: BIMADU; ISSN: 0142-9612

DOCUMENT TYPE: Journal LANGUAGE: English

A series of oligoethylene oxide monoalkyl(aryl) alc. ethers was grafted on to the backbone of a polytetramethylene oxide (PTMO) -based polyurethane, in an attempt to improve its biocompatibility. Each polyurethane contained a different pendant chain grafted to the urethane nitrogen atoms. The grafted chains consisted of various short lengths of hydrophilic oligomeric poly(ethylene oxide) (PEO) spacer segments and alkyl/aryl hydrophobic terminal groups. By using the 1H-NMR technique, the extent of grafting was found to range from 7 to 12 mol% substitution of the urethane hydrogen groups. The surface properties of these materials were evaluated using high-vacuum, air-equilibrated and water-equilibrated methods. XPS and static and dynamic contact angle expts. were performed. XPS showed that all of the grafted polyurethane surfaces contained higher ratios of C1s to O1s than the base polyurethane. These C:O contents correlate with the C:O ratios of the grafted chains. Dynamic contact angle anal. showed larger contact angle hysteresis for the grafted polyurethanes. The grafted polyurethanes generally exhibit lower complement activation, measured by an in vitro assay for C3a. A canine ex vivo arteriovenous series shunt was used to monitor platelet and fibrinogen deposition on these polymers. The incorporation of short ethylene oxide spacer segments with terminal C18 linear alkyl chains resulted in an improved short-term (up to 15 min) blood compatibility compared to the underivatized polyurethane. At longer blood contact times, all the grafted polyurethanes were more thrombogenic than the base polyurethane. In addn., there was no observable correlation between the material surface properties and the blood contact response.

L1 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1992:557571 HCAPLUS

DOCUMENT NUMBER: 117:157571

TITLE: The effect of surface hydrophilicity on

biomaterial-leukocyte interactions

AUTHOR(S):

Lim, Florencia; Cooper, Stuart L.

CORPORATE SOURCE:

Dep. Chem. Eng., Univ. Wisconsin, Madison, WI, 53706,

USA

SOURCE:

ASAIO Transactions (1991), 37(3), M146-M147

CODEN: ASATEJ; ISSN: 0889-7190

DOCUMENT TYPE:

Journal English

LANGUAGE:

Leukocyte adhesion onto a series of polyetherurethanes contg. various ratios of polyethylene oxide (PEO) to polytetramethylene oxide (PTMO) in the soft segment was evaluated using an in vitro series shunt. The deposition of polymorphonuclear (PMN) and mononuclear (MN) leukocytes was measured quant. using labeling techniques. Results showed that H/H-1, the most hydrophobic surface, adsorbed higher amts. of PMN leukocytes. It was also obsd. that for most materials the no. of PMN and MN leukocytes deposited reached a plateau within 15 min. Unlike MN adherence, the presence of plasma proteins increased the no. of PMN leukocytes deposited on the materials.

Sims/EIC 3700

```
FILE 'HCAPLUS' ENTERED AT 09:33:28 ON 22 MAY 2003
L1 2838 S POLYCARBONATE? (S) POLYURETHANE?
        217652 S AROMATIC?
L3
          37 S L1 AND L2
L4
        26749 S BALLOON? OR CATHETER?
L5
            0 S L3 AND L4
L6
            37 S L2 AND L4
L7
        15702 S CATHETER?
L8
        12359 S BALLOON?
        1161 S L7(S)L8
L9
           1 S L2 AND L9
L10
        554826 S COPOLYMER? OR CO() POLYMER?
L11
        116840 S POLYURETHANE?
L12
        0 S L2(S)L11(S)S12
L13
         2701 S L2(S)L11
L14
L15
          543 S L2(S)L12
         3218 S L14 OR L15
L16
L17
        53622 S POLYCARBONATE? OR POLY() CARBONATE?
          135 S L16 AND L17
L18
           0 S L7 AND L18
L19
           46 S L8 AND L17
L20 ·
           46 DUP REMOVE L20 (0 DUPLICATES REMOVED)
L21
L22
        72060 S AROMATIC/AB
          46 S L21
Ĺ23
            0 S L21 AND L22
L24
        362353 S L11/AB
L25
        75487 S L12/AB
L26
         14695 S L7/AB
L27
L28
         11249 S L8/AB
         2521 S L22 AND L25
L29
          51 S L26 AND L29
L30
            3 S L17 AND L30
L31
```

```
Items
               Description
        31073
               BALLOON (S) CATHETER?
S2
          11
               BIONATE
S3
           5
               RD (unique items)
S4
          94
               POLY() CARBONATE() URETHANE?
S5
        29842
               POLYCARBONATE? OR POLY()CARBONATE?
S6
       79613
               URETHANE? OR POLYURETHANE? OR POLY() URETHANE?
S7
     . 307437
               AROMATIC?
               CARBONATE? (3N) URETHANE?
S8
         222
       222
S9
               S4 OR S8
S10
         581
               S5 (3N) S6
S11
         650
               S9 OR S10
S12
          33
               S7(S)S11
S13
          0
               S1 AND S12
S14
          33
               S12
S15
          18
               RD (unique items)
S16
          11
               AU='LIM FLORENCIA'
         10 RD (unique items)
S17
S18 145187
               BALLOON?
S19
           0
               S12 AND S18
S20
          52
               S7 AND S18
S21
          0
               S20 AND S5
S22
          52
               S20
S23
          42
               RD (unique items)
S24
         446
               S7(3N)(S4 OR S6 OR S8)
S25
           0
               S18 AND S24
? show files
       2:INSPEC 1969-2003/May W2
         (c) 2003 Institution of Electrical Engineers
File
       5:Biosis Previews(R) 1969-2003/May W3
         (c) 2003 BIOSIS
File
       6:NTIS 1964-2003/May W3
         (c) 2003 NTIS, Intl Cpyrght All Rights Res
File
       8:Ei Compendex(R) 1970-2003/May W2
         (c) 2003 Elsevier Eng. Info. Inc.
File 34:SciSearch(R) Cited Ref Sci 1990-2003/May W3
         (c) 2003 Inst for Sci Info
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 1998 Inst for Sci Info
File 73:EMBASE 1974-2003/May W3
         (c) 2003 Elsevier Science B.V.
File 155:MEDLINE(R) 1966-2003/May W3
```

(c) format only 2003 The Dialog Corp.

```
ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
AN
     1999:390394 HCAPLUS
DN
     131:35905
     Polyketone rubber-based medical devices with improved properties
ΤI
IN
     Thakrar, Ashok; Gandhi, Deepak; Tenhoff, Harm
PA
     Intella Interventional Systems, Inc., USA
     PCT Int. Appl., 57 pp.
SO
     CODEN: PIXXD2
DΤ
     Patent
     English
LA
IC
     A61L029-00
CC
     63-7 (Pharmaceuticals)
     Section cross-reference(s): 39
FAN.CNT 2
     PATENT NO.
                     KIND DATE
                                          APPLICATION NO.
                                                            DATE
                     ----
                                          ______
     -----
                                                           -----
PΙ
     WO 9929353
                     A2
                           19990617
                                          WO 1998-US26413 19981211
     WO 9929353
                     Α3
                           19991028
            AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
            KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
            MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
            TR, TT, UA
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6099926
                            20000808
                                          US 1997-989791
                                                            19971212
                      Α
     US 6093463
                       Α
                            20000725
                                          US 1998-45483
                                                            19980320
     AU 9918200
                      A1
                            19990628
                                          AU 1999-18200
                                                            19981211
     EP 1037677
                      A2
                            20000927
                                          EP 1998-963100
                                                            19981211
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2001525228
                      T2
                            20011211
                                          JP 2000-524022
                                                            19981211
PRAI US 1997-989791
                      A2
                            19971212
     US 1998-45483
                      A2
                            19980320
     WO 1998-US26413
                     W
                            19981211
     Medical devices, comprising a polymer or polymeric compn., wherein the
     phys. properties (e.g., glass transition temp., elasticity, elongation,
     friction, and tangential tensile strength) of the polymers or polymeric
     compns. or of the devices themselves are specified, used as intraluminal
     balloons and intravascular or intracoronary catheters
     are described. A molding compn. was prepd. by compounding 30 wt.% of
     aliph. polyketone R-1000 with 70 wt.% Pebax 6333 on a 27 mm twin screw
     extruder. The extruded blend was pelletized and then reextruded into a
     0.019/0.038 in. ID/OD tube using a 25 mm single screw extruder at
     420-480.degree.F. Test pieces, including 2.5 mm diam. balloons, were
     prepd. and tested, showing a coeff. of friction in air and water of 0.1214
     and 0.1160, resp., tensile strength of 13128 psi, elongation of 188%, and
     burst pressure of 10 atm.
ST
     polyketone thermoplastic rubber balloon catheter
IT
     Sulfonamides
     Sulfonamides
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
     USES (Uses)
        (arenesulfonamides, plasticizers; polyketone and thermoplastic
        rubber-based medical devices with improved properties)
IT
     Synthetic rubber, biological studies
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
```

#### pellegrino (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (azacyclotridecanone-polytetramethylene glycol, block, Pebax 6333; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Medical goods (catheters, intracoronary and intravascular; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Medical goods (catheters; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Polyolefins RL: DEV (Device component use); MOA (Modifier or additive use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (epoxy-contg., coupling agents; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Medical goods (intraluminal balloons; polyketone and thermoplastic rubber-based medical devices with improved properties) TT Medical goods (percutaneous devices; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Crosslinking (photochem.; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Amides, biological studies Epoxides Esters, biological studies RL: DEV (Device component use); MOA (Modifier or additive use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (plasticizers; polyketone and thermoplastic rubber-based medical devices with improved properties) ΤТ Synthetic rubber, biological studies RL: DEV (Device component use); POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyamide-polyether, block; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Synthetic rubber, biological studies RL: DEV (Device component use); POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyamide; polyketone and thermoplastic rubber-based medical devices with improved properties) IT Coupling agents Crosslinking agents Elongation, mechanical Friction

Glass transition temperature
Plasticizers
Tensile strength
Young's modulus
 (polyketone and thermoplastic rubber-based medical devices with improved properties)
Acrylic rubber
Urethane rubber, biological studies
RL: DEV (Device component use); MOA (Modifier or additive use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyketone and thermoplastic rubber-based medical devices with

ΙŢ

```
improved properties)
     Fluoropolymers, biological studies
IT
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone and thermoplastic rubber-based medical devices with
        improved properties)
ΙT
     Polyester rubber
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone and thermoplastic rubber-based medical devices with
        improved properties)
TΤ
     Polyesters, biological studies
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone and thermoplastic rubber-based medical devices with
        improved properties)
IT
     Thermoplastic rubber
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone and thermoplastic rubber-based medical devices with
        improved properties)
IT
     Synthetic rubber, biological studies
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone; polyketone and thermoplastic rubber-based medical devices
        with improved properties)
TT
     Synthetic rubber, biological studies
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
    USES (Uses)
        (polyoxymethylene; polyketone and thermoplastic rubber-based medical
        devices with improved properties)
TT
     Crosslinking
        (radiochem.; polyketone and thermoplastic rubber-based medical devices
        with improved properties)
TΤ
    Medical goods
        (stents, catheters for delivery of; polyketone and thermoplastic
        rubber-based medical devices with improved properties)
IT
    Aromatic compounds
       Aromatic compounds
    RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
    USES (Uses)
        (sulfonamides, plasticizers; polyketone and thermoplastic rubber-based
        medical devices with improved properties)
IT
    Crosslinking
        (thermal; polyketone and thermoplastic rubber-based medical devices
        with improved properties)
IT
    Fluoro rubber
    RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
    USES (Uses)
        (vinylidene fluoride; polyketone and thermoplastic rubber-based medical
       devices with improved properties)
IT
    7440-32-6D, Titanium, org. compds., biological studies
    RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
    USES (Uses)
        (coupling agents; polyketone and thermoplastic rubber-based medical
```

```
devices with improved properties)
IT
     97-90-5, Ethylene glycol dimethacrylate
                                               101-37-1
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
     USES (Uses)
        (crosslinking agent; polyketone and thermoplastic rubber-based medical
        devices with improved properties)
IT
     1025-15-6
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
        (crosslinking agents; polyketone and thermoplastic rubber-based medical
        devices with improved properties)
     64-19-7, Acetic acid, biological studies
                                                77-93-0, Triethyl citrate
TΤ
     110-94-1, Pentanedioic acid
                                   123-99-9, Nonanedioic acid, biological
             124-04-9, Hexanedioic acid, biological studies
                                                                2500-57-4
     2664-42-8, N,N-Dimethyl oleamide
                                        3622-84-2, Plasthall BSA
                                                                   35415-33-9
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
     USES (Uses)
        (plasticizer; polyketone and thermoplastic rubber-based medical devices
        with improved properties)
     77-92-9D, Citric acid, esters
                                     7664-38-2D, Phosphoric acid, alkyl and
     arom. esters, biological studies
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
     USES (Uses)
        (plasticizers; polyketone and thermoplastic rubber-based medical
        devices with improved properties)
     7440-67-7D, Zirconium, org. compds., biological studies
IT
                  25014-41-9, Polyacrylonitrile
     Polyethylene
     RL: DEV (Device component use); MOA (Modifier or additive use); POF
     (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study);
     USES (Uses)
        (polyketone and thermoplastic rubber-based medical devices with
        improved properties)
                            24937-79-9
                                         25038-59-9, biological studies
ΙT
     24937-16-4, Nylon 12
     88995-51-1, Carilon R-1000
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone and thermoplastic rubber-based medical devices with
        improved properties)
IT
     227030-43-5, Carilon DX 26HW100
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (polyketone; polyketone and thermoplastic rubber-based medical devices
        with improved properties)
     108548-63-6, Azacyclotridecanone-polytetramethylene glycol block copolymer
IT
     RL: DEV (Device component use); POF (Polymer in formulation); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (rubber; polyketone and thermoplastic rubber-based medical devices with
        improved properties)
```